scholarly journals Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Kisaburo Yamada ◽  
Kenichi Kimoto ◽  
Hirofumi Kono ◽  
Toshiaki Kubota
Keyword(s):  
Macular Degeneration ◽  
Intravitreal Bevacizumab ◽  
Age Related Macular Degeneration ◽  
Rank Test ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Signed Rank ◽  
Significant Difference ◽  
Signed Rank Test ◽  
Ranibizumab Treatment

Purpose. To report our experiences in patients with age-related macular degeneration (AMD) treated initially with intravitreal ranibizumab and then switched to bevacizumab. Methods. We retrospectively reviewed the records of 7 patients (7 eyes) who were treated with monthly injections of intravitreal ranibizumab and then switched to injections of bevacizumab (every 6 weeks) for six months. The best-corrected visual acuity measurements (BCVA) and optical coherence tomography (OCT) were performed at the baseline examination and then at each visit. The Wilcoxon signed-rank test was used for the statistical analysis. Results. Following three monthly ranibizumab treatments, there was no significant difference in the BCVA, while the foveal retinal thickness (FRT) significantly decreased (). Switching from ranibizumab to bevacizumab resulted in maintenance (57.2%) of the BCVA and a further decrease in the FRT () after 6 months. Conclusions. Switching to intravitreal bevacizumab may be effective in patients who wish to discontinue intravitreal ranibizumab treatment due to the high cost.

Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events

2019 ◽  
Vol 30 (1) ◽  
pp. 66-71
Author(s):  
Orly Weinstein ◽  
Muhammad Abu Tailakh ◽  
Tova Lifshitz ◽  
Victor Novack ◽  
Jaime Levy
Keyword(s):  
Acute Coronary Syndrome ◽  
Macular Degeneration ◽  
Intravitreal Bevacizumab ◽  
Age Related Macular Degeneration ◽  
Thromboembolic Events ◽  
Coronary Syndrome ◽  
Intravitreal Bevacizumab Injection ◽  
Age Related ◽  
Significant Difference ◽  
Bevacizumab Injection

Background: Systemic complications of intravitreal anti-vascular endothelial growth factor agents are relatively uncommon but highly significant. Objectives: Primary objective: To assess the risk for thromboembolic events following intravitreal bevacizumab injection in neovascular age-related macular degeneration patients by a large population-based study. Secondary objective: To analyze the association between injection frequency and the risk for thromboembolic events, the time interval between the injection and the thromboembolic events, and the influence of chronic diseases on complications rate. Design: A retrospective cohort study. Methods: Consecutive neovascular age-related macular degeneration patients receiving intravitreal bevacizumab at Soroka University Medical Center from December 2005 to December 2013 were included. Thromboembolic events analyzed included acute coronary syndrome, acute myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism. The thromboembolic event rate was compared 2 years prior and 2 years after the initial intravitreal bevacizumab injection. Results: A total of 2102 patients were included. Acute coronary syndrome and stroke rate were higher 2 years after intravitreal bevacizumab (p = 0.03 and p = 0.01, respectively). No statistical significant difference was found for the rest of thromboembolic events. Patients older than 80 years and patients receiving less than six intravitreal bevacizumab injections were more likely to experience stroke. Patients with known cardiovascular risk factors before starting injections did not develop significant more thromboembolic events. Conclusion: In our study population, patients treated with intravitreal bevacizumab were significantly more likely to experience stroke during 2 years after first injection.

scholarly journals Intravitreal Ranibizumab Treatment and Treatment Regimens in Wet-Form (Neovascular) Age-Related Macular Degeneration

2017 ◽  
pp. 189-197
Keyword(s):  
Macular Degeneration ◽  
Progressive Disease ◽  
Vision Loss ◽  
Age Related Macular Degeneration ◽  
Therapeutic Tool ◽  
Intravitreal Ranibizumab ◽  
Treatment Regimens ◽  
Age Related ◽  
Ranibizumab Treatment

Age-related macular degeneration (AMD) is a chronic and progressive disease of the central retina that causes vision loss in people over 50 years of age. With an understanding of the role of VEGF in AMD, intravitreal anti-VEGF agents are used as the most important therapeutic tool in the management of AMD. In this review we try to discuss intravitreal ranibizumab treatment and treatment regimens in wet (neovascular) age-related macular degeneration.

scholarly journals Long term intravitreal ranibizumab treatment for exsudative age-related macular degeneration

2013 ◽  
Vol 154 (45) ◽  
pp. 1790-1797 ◽  
Author(s):  
Regina Lukács ◽  
Miklós Resch ◽  
András Papp ◽  
Antal Szabó ◽  
Ágnes Borbándy ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Retinal Thickness ◽  
Age Related Macular Degeneration ◽  
Central Retinal Thickness ◽  
First Year ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Pro Re Nata ◽  
Ranibizumab Treatment

Introduction: The results of intravitreal ranibizumab treatment for exsudative age-related macular degeneration have been favourable until this time. Aim: To evaluate the two-year functional and anatomic results of intravitreal ranibizumab treatment. Method: 46 patients (age: 75±9.1 years) were included in a prospective single center study. Treatment regimen was the following: monthly 0.5 mg ranibizumab was administered in the first 3 months, and later as required (pro re nata). The change of best corrected visual acuity and central retinal thickness was followed. Results: The visus change at the end of the follow-up time was not statistically significant compared to baseline (p = 0.760) and the at the end of the first year (p = 0.154). Central retinal thickness decreased significantly compared to baseline (p = 0.000001), but the change was not statistically significant compared to the end of the first year (p = 0.875). Conclusions: Patients with neovascular macular degeneration treated with intravitreal ranibizumab using pro re nata regimen have stable visus for long term, and the exsudation could be reduced efficiently. Orv. Hetil., 154(45), 1790–1797.

Factors Associated With the Response of Age-Related Macular Degeneration to Intravitreal Ranibizumab Treatment

2012 ◽  
Vol 154 (1) ◽  
pp. 125-136 ◽  
Author(s):  
Kenji Yamashiro ◽  
Kaoruko Tomita ◽  
Akitaka Tsujikawa ◽  
Isao Nakata ◽  
Yumiko Akagi-Kurashige ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Factors Associated ◽  
Age Related ◽  
Ranibizumab Treatment

scholarly journals Comparison of Progression Rate of Retinal Pigment Epithelium Loss in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Aflibercept

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Juliana Wons ◽  
Magdalena A. Wirth ◽  
Nicole Graf ◽  
Matthias D. Becker ◽  
Stephan Michels
Keyword(s):  
Retinal Pigment Epithelium ◽  
Macular Degeneration ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Age Related Macular Degeneration ◽  
Progression Rate ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Significant Difference ◽  
One Year

Purpose. Retinal pigment epithelium (RPE) loss in neovascular age-related macular degeneration (nAMD) seem to have a linear progression but might be influenced by the treatment. The purpose of the study is the comparison of RPE loss over three years in patients treated with intravitreal ranibizumab to patients who were switched to aflibercept. Methods. A retrospective analysis with 96 eyes switched to aflibercept was conducted. The progression rate of RPE loss was evaluated in patients who showed atrophy one year prior to switch (n=17) or on switch date (n=19). The RPE loss was evaluated by spectral domain optical coherence tomography (SD-OCT). Further, 22 eyes from patients treated with ranibizumab were compared. Results. The median yearly progression of RPE loss after square root transformation showed no significant difference in the year prior to switch compared to the year after switch (p=0.854). In patients who received only ranibizumab, the median yearly progression of RPE loss was 0.15 mm/y, for aflibercept patients, 0.13 mm/y. This difference was not statistically significant (p=0.172). Conclusions. There seems to be a linear progression rate of RPE loss in patients treated with ranibizumab as well as in patients with aflibercept. No significant increase of progression rate was found after switch to aflibercept.

Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment

2011 ◽  
Vol 91 (1) ◽  
pp. 42-47 ◽  
Author(s):  
Sara B. Bloch ◽  
Morten la Cour ◽  
Birgit Sander ◽  
Louise K. H. Hansen ◽  
Josefine Fuchs ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Visual Outcome ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Ranibizumab Treatment
Sign in / Sign up

Export Citation Format

Share Document